Testing a CAR T immune cell therapy, BCB-276, for children and young adults with DIPG
Original title: Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG).
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a middle stage test in people, so we do not know yet if it helps.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study is testing an immune cell therapy for DIPG, given after radiation.
Who this trial is for. This trial is for children and young adults with DIPG, a rare and aggressive brain tumor. To join, a person must be between 1 and 26 years old, and must enroll within 6 weeks of finishing their first radiation therapy. The trial is testing BCB-276, a therapy made from a person's own immune cells that are changed in a lab to find and attack cancer cells. It is given into the fluid around the brain through a catheter, every 2 weeks at a research center.
Where it stands. This trial has not reported results. It is looking at whether BCB-276 is safe, and whether it helps people with DIPG live longer. Those answers are not in yet. Being in the study also means travel to a study site, procedures to give the treatment, and check-ups that can last up to about 2 years.
What this means, and what it doesn't
What it could mean: There are few treatment options for DIPG, and this is one of the ideas being tested. If this sounds like it might fit your situation, you can ask your care team about it. They can explain what taking part would involve and whether it makes sense for you.
What it doesn't mean: This does not mean BCB-276 works. A trial is a test, not a proven treatment. Joining a study is not a guarantee that it will help, and it is not a promise of a cure. Whether someone can join is decided by the trial team, not by us.
Source: ClinicalTrials.gov, August 4, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.